⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31612604 | 0.84 | ADRA1D (0.37) | — | |
| SCHEMBL506796 | 0.81 | — | — | |
| SCHEMBL9769184 | 0.77 | — | — | |
| SCHEMBL28748248 | 0.77 | — | — | |
| SCHEMBL13510846 | 0.77 | — | — | |
| SCHEMBL31125049 | 0.75 | LTB4R (0.42) | — | |
| SCHEMBL11725099 | 0.74 | ADRA1D (0.39) | — | |
| SCHEMBL25239748 | 0.74 | ADRA1D (0.36) | — | |
| SCHEMBL31125025 | 0.74 | CAPN1 (0.37) | — | |
| SCHEMBL10947172 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025049326-A1 | TRICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | BIOCRYST PHARMACEUTICALS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| EP-3814331-B1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | ORSOBIO INC (US) | 2023-06-14 | — | — | EP | disclosed |
| US-11667630-B2 | Nitrogen-containing 6-membered cyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2023-06-06 | — | — | US | disclosed |
| US-11667630-B2 | Nitrogen-containing 6-membered cyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2023-06-06 | — | — | US | disclosed |
| US-11667630-B2 | Nitrogen-containing 6-membered cyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2023-06-06 | — | — | US | disclosed |
| EP-3733665-B1 | 2-OXO-1,3,4-THIADIAZINAN-3-YL MOIETY CONTAINING COMPOUNDS WITH EP4 RECEPTOR AGONIST ACTIVITY | ASAHI KASEI PHARMA CORP (JP) | 2022-09-28 | — | — | EP | disclosed |
| US-20210188837-A1 | NITROGEN-CONTAINING 6-MEMBERED CYCLIC COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2021-06-24 | — | — | US | disclosed |
| US-20210188837-A1 | NITROGEN-CONTAINING 6-MEMBERED CYCLIC COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2021-06-24 | — | — | US | disclosed |
| US-10988468-B2 | Nitrogen-containing 6-membered cyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2021-04-27 | — | — | US | disclosed |
| US-10988468-B2 | Nitrogen-containing 6-membered cyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2021-04-27 | — | — | US | disclosed |
| US-20200347046-A1 | NITROGEN-CONTAINING 6-MEMBERED CYCLIC COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2020-11-05 | — | — | US | disclosed |
| US-20200347046-A1 | NITROGEN-CONTAINING 6-MEMBERED CYCLIC COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2020-11-05 | — | — | US | disclosed |
| EP-3733665-A1 | NITROGEN-CONTAINING SIX-MEMBERED RING COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2020-11-04 | — | — | EP | disclosed |
| EP-3733665-A1 | NITROGEN-CONTAINING SIX-MEMBERED RING COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2020-11-04 | — | — | EP | disclosed |
| EP-1003751-A1 | HYDROXAMIC ACID SUBSTITUTED FUSED HETEROCYCLIC METALLOPROTEINASE INHIBITORS | AMGEN INC. (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999006410-A1 | HYDROXAMIC ACID SUBSTITUTED FUSED HETEROCYCLIC METALLOPROTEINASE INHIBITORS | AMGEN INC. (US) | 1999-02-11 | — | — | WO | disclosed |